Literature DB >> 20816493

Aminoglycosides redesign strategies for improved antibiotics and compounds for treatment of human genetic diseases.

Varvara Pokrovskaya1, Igor Nudelman, Jeyakumar Kandasamy, Timor Baasov.   

Abstract

Aminoglycosides are highly potent, broad-spectrum antibiotics that kill bacteria by binding to the ribosomal decoding site and reducing the fidelity of protein synthesis. The emergence of bacterial strains resistant to these drugs, as well as their relative toxicity, have inspired extensive searches toward the goal of obtaining novel molecular designs with improved antibacterial activity and reduced toxicity. In recent years, a new therapeutic approach that employs the ability of certain aminoglycosides to induce mammalian ribosomes to readthrough premature stop codon mutations has emerged. This new and challenging task has introduced fresh research avenues in the field of aminoglycosides research. In this chapter, our recent observations and current challenges in the design of aminoglycosides with improved antibacterial activity and the treatment of human genetic diseases are discussed. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20816493     DOI: 10.1016/S0076-6879(10)78021-6

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  11 in total

1.  The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.

Authors:  Dan Wang; Valery Belakhov; Jeyakumar Kandasamy; Timor Baasov; Su-Chen Li; Yu-Teh Li; David M Bedwell; Kim M Keeling
Journal:  Mol Genet Metab       Date:  2011-10-19       Impact factor: 4.797

Review 2.  New developments in aminoglycoside therapy and ototoxicity.

Authors:  Jing Xie; Andra E Talaska; Jochen Schacht
Journal:  Hear Res       Date:  2011-05-27       Impact factor: 3.208

Review 3.  Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infections.

Authors:  Kristin J Labby; Sylvie Garneau-Tsodikova
Journal:  Future Med Chem       Date:  2013-07       Impact factor: 3.808

4.  Selectively guanidinylated aminoglycosides as antibiotics.

Authors:  Richard J Fair; Mary E Hensler; Wdee Thienphrapa; Quang N Dam; Victor Nizet; Yitzhak Tor
Journal:  ChemMedChem       Date:  2012-05-25       Impact factor: 3.466

Review 5.  New treatment options for hearing loss.

Authors:  Ulrich Müller; Peter G Barr-Gillespie
Journal:  Nat Rev Drug Discov       Date:  2015-03-20       Impact factor: 84.694

6.  Pharmacological read-through of R294X Mecp2 in a novel mouse model of Rett syndrome.

Authors:  Jonathan K Merritt; Bridget E Collins; Kirsty R Erickson; Hongwei Dong; Jeffrey L Neul
Journal:  Hum Mol Genet       Date:  2020-08-29       Impact factor: 6.150

7.  Nephroprotective effect of catechin on gentamicin-induced experimental nephrotoxicity.

Authors:  Ankush Sardana; Sanjeev Kalra; Deepa Khanna; Pitchai Balakumar
Journal:  Clin Exp Nephrol       Date:  2014-05-14       Impact factor: 2.801

8.  Characterization of the stop codon readthrough signal of Colorado tick fever virus segment 9 RNA.

Authors:  Sawsan Napthine; Christina Yek; Michael L Powell; T David K Brown; Ian Brierley
Journal:  RNA       Date:  2011-12-21       Impact factor: 4.942

Review 9.  Overcoming Aminoglycoside Enzymatic Resistance: Design of Novel Antibiotics and Inhibitors.

Authors:  Sandra G Zárate; M Luisa De la Cruz Claure; Raúl Benito-Arenas; Julia Revuelta; Andrés G Santana; Agatha Bastida
Journal:  Molecules       Date:  2018-01-30       Impact factor: 4.411

10.  Aminoglycoside-stimulated readthrough of premature termination codons in selected genes involved in primary ciliary dyskinesia.

Authors:  Zuzanna Bukowy-Bieryllo; Maciej Dabrowski; Michał Witt; Ewa Zietkiewicz
Journal:  RNA Biol       Date:  2016-08-12       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.